Acquisition by Lloyd Segal of 40000 shares of Repare Therapeutics subject to Rule 16b-3
| RPTX Stock | USD 1.54 0.02 1.32% |
Slightly above 53% of Repare Therapeutics' investors are presently thinking to get in. The analysis of overall sentiment of trading Repare Therapeutics stock suggests that some investors are interested at this time. Repare Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Repare Therapeutics' earnings reports, geopolitical events, and overall market trends.
Filed transaction by Repare Therapeutics Director, Officer President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Repare Therapeutics Fundamental Analysis
We analyze Repare Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Repare Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Repare Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Repare Therapeutics is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Repare Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Repare Therapeutics stock to make a market-neutral strategy. Peer analysis of Repare Therapeutics could also be used in its relative valuation, which is a method of valuing Repare Therapeutics by comparing valuation metrics with similar companies.
Peers
Repare Therapeutics Related Equities
| REPL | Replimune | 10.68 | ||||
| NRIX | Nurix Therapeutics | 2.17 | ||||
| MRUS | Merus BV | 2.09 | ||||
| KYMR | Kymera Therapeutics | 1.58 | ||||
| MASS | 908 Devices | 2.76 | ||||
| RLAY | Relay Therapeutics | 3.29 | ||||
| RAPT | RAPT Therapeutics | 6.13 |
Additional Tools for Repare Stock Analysis
When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.